Internal Diseases and Therapy · MU Sofia

66. Myeloma multiplex

Covers multiple myeloma as a plasma cell dyscrasia, starting with its definition and classification by immunoglobulin type, then its epidemiology and suspected genetic role. It contrasts the precursor state MGUS with diagnostic criteria for myeloma, describes typical presentations such as anaemia, bone pain and infections, and outlines key tests, including a serum protein electrophoresis trace. It closes with brief notes on indolent disease and treatment options.

Inside: 1 section · 1 labelled picture · 15 flashcards · 3 min

Topic 66 of 139 in the MU Sofia syllabus for Internal Diseases and Therapy (Medicine, Years 4 and 5). The free AceMed note covers it in 1 section, about 463 words (3 min of reading), with 15 flashcards.

In this note

  1. Myeloma multiplex

Myeloma multiplex

Myeloma multiplex = multiple myeloma = myeloma

Myeloma is a haematological cancer characterized by clonal proliferation of plasma cells (and their associated antibodies) in the bone marrow. The massive proliferation of immunoglobulins causes systemic dysfunction in many organs, especially the kidneys.

We classify myeloma based on the type of immunoglobulin that is produced, be that IgG (⅔), IgA (⅓) or IgM or D, the latter two being exceptionally rare.

Myeloma is a so-called plasma cell dyscrasia (dyscrasia a = disordered state), and is often associated with osteolytic bone disease, anaemia and renal failure. Incidence is about 5/100,000 with the median age at diagnosis of 72 y.o., the condition has a prevalence for black males.

There is no clear etiology, however there is some genetic role with familial studies showing links, although no single genes have been identified.

So, multiple myeloma cells arise from post germinal (terminally differentiated) B-cells (aka plasma cells). These cells secrete IgG or IgM into the serum and urine, along with impairing normal immunoglobulin production, leading to relative hypogammaglobulinemia and increasing the risk of infection.

There exists a precursor condition to Multiple Myeloma, the so-called monoclonal gammopathy of undetermined significance (MGUS). MGUS is an increase in Ig in the body but with no end organ damage and clonal bone marrow plasma <10%. In contrast, multiple myeloma cannot be diagnosed until clonal bone marrow plasma >10% OR one of the following events occurs:

  • Evidence of end organ damage due to
  • Hypercalcaemia
  • Renal insufficiency
  • Anemia
  • Bone lesions - one or more
  • Any of the following biomarkers of malignancy
  • Clonal bone marrow plasma cell percentage >60%
  • Involved:uninvolved serum free light-chain ratio >100

Patients most commonly present with lethargy secondary to anaemia and bone pain (most commonly in the back). The bone pain is the result of a build up of plasma cells in the bone marrow that causes osteolysis. MM can also present as a medical emergency secondary to sepsis, hypercalcaemia, hyperviscosity symptoms and/or spinal cord compression due to vertebral lesions.

In all over 50s with back pain do serum protein electrophoresis and ESR. Patients may present with recurrent bacterial infections, hypercalcaemia and/or proteinuria secondary to renal impairment.

The key diagnostic test is the serum and/or urine electrophoresis for detection of the excess Ig. Bone marrow biopsy is also definitive. Imaging to assess bone disease is essential in all patients due to the prevalence of osteolytic lesions.

Continue reading free

The whole note is free with an AceMed account, with its 15 flashcards. Premium adds flashcard recall, highlights and Ask AI.